These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30132140)

  • 1. Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis.
    Weernink MGM; Vaanholt MCW; Groothuis-Oudshoorn CGM; von Birgelen C; IJzerman MJ; van Til JA
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):493-502. PubMed ID: 30132140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review.
    Wilke T; Bauer S; Mueller S; Kohlmann T; Bauersachs R
    Patient; 2017 Feb; 10(1):17-37. PubMed ID: 27461276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis.
    van Til J; Oudshoorn-Groothuis C; Weernink M; von Birgelen C
    Patient; 2020 Aug; 13(4):445-455. PubMed ID: 32329020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Country-based Comparison of Atrial Fibrillation Patients' Preferences for Oral Anticoagulation: An Evaluation of Discrete Choice Experiments in Five Different Countries.
    Henry M; Wosnitza M; Thate-Waschke IM; Bauersachs R; Ueng KC; Chang KC; Wilke T
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):100-106. PubMed ID: 33165142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation.
    Kaiser K; Cheng WY; Jensen S; Clayman ML; Thappa A; Schwiep F; Chawla A; Goldberger JJ; Col N; Schein J
    Curr Med Res Opin; 2015 Dec; 31(12):2261-72. PubMed ID: 26390360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences for anticoagulation therapy in atrial fibrillation: the patients' view.
    Böttger B; Thate-Waschke IM; Bauersachs R; Kohlmann T; Wilke T
    J Thromb Thrombolysis; 2015 Nov; 40(4):406-15. PubMed ID: 26260625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis.
    Lane DA; Meyerhoff J; Rohner U; Lip GYH
    Clin Cardiol; 2018 Jun; 41(6):855-861. PubMed ID: 29696664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preferences for oral anticoagulant treatment in the medium and long term prevention of stroke in non valvular atrial fibrillation].
    González-Rojas N; Giménez E; Fernández MÁ; Heineger AI; Martínez JL; Villar J; Lizán L
    Rev Neurol; 2012 Jul; 55(1):11-9. PubMed ID: 22718404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies.
    Shafrin J; Bruno A; MacEwan JP; Campinha-Bacote A; Trocio J; Shah M; Tan W; Romley JA
    Value Health; 2016 Jun; 19(4):451-9. PubMed ID: 27325337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
    Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
    Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.
    Andrade JG; Krahn AD; Skanes AC; Purdham D; Ciaccia A; Connors S
    Can J Cardiol; 2016 Jun; 32(6):747-53. PubMed ID: 26774235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.
    Clarkesmith DE; Pattison HM; Lane DA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008600. PubMed ID: 23736948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).
    Ansell J; Hollowell J; Pengo V; Martinez-Brotons F; Caro J; Drouet L
    J Thromb Thrombolysis; 2007 Apr; 23(2):83-91. PubMed ID: 17221328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.
    Ageno W; Beyer-Westendorf J; Rubboli A
    Expert Opin Pharmacother; 2017 Sep; 18(13):1325-1332. PubMed ID: 28786696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants in cardiovascular disease.
    Gallego P; Roldán V; Lip GY
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):34-44. PubMed ID: 24038020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceived advantages and disadvantages of oral anticoagulants, and the trade-offs patients make in choosing anticoagulant therapy and adhering to their drug regimen.
    Vaanholt MCW; Weernink MGM; von Birgelen C; Groothuis-Oudshoorn CGM; IJzerman MJ; van Til JA
    Patient Educ Couns; 2018 Nov; 101(11):1982-1989. PubMed ID: 30001822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.